Open Financial Statements From 2010 to 2025
| OPORF Stock | USD 0.24 0.00 0.00% |
Check Open Orphan financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Open Orphan's main balance sheet or income statement drivers, such as , as well as many indicators such as . Open financial statements analysis is a perfect complement when working with Open Orphan Valuation or Volatility modules.
Open |
Open Orphan plc Company Return On Equity Analysis
Open Orphan's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Open Orphan Return On Equity | -0.05 |
Most of Open Orphan's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Open Orphan plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Open Orphan plc has a Return On Equity of -0.05. This is 99.79% lower than that of the Healthcare sector and 99.86% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 83.87% lower than that of the firm.
Open Orphan plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Open Orphan's current stock value. Our valuation model uses many indicators to compare Open Orphan value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Open Orphan competition to find correlations between indicators driving Open Orphan's intrinsic value. More Info.Open Orphan plc is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Open Orphan's earnings, one of the primary drivers of an investment's value.About Open Orphan Financial Statements
Open Orphan stakeholders use historical fundamental indicators, such as Open Orphan's revenue or net income, to determine how well the company is positioned to perform in the future. Although Open Orphan investors may analyze each financial statement separately, they are all interrelated. For example, changes in Open Orphan's assets and liabilities are reflected in the revenues and expenses on Open Orphan's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Open Orphan plc. Please read more on our technical analysis and fundamental analysis pages.
Open Orphan Plc operates as a pharmaceutical service and contract research company. Further, the company provides preclinical and early clinical research services sales and marketing services and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC , and PK and medical writing to a range of European clients. Open Orphan is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Open Pink Sheet
Open Orphan financial ratios help investors to determine whether Open Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Open with respect to the benefits of owning Open Orphan security.